Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab

24th June 2021 Uncategorised 0

Preparations come on the heels of positive results from the Phase II ARC-7 study

More: Arcus, Gilead prep Phase III studies of anti-TIGIT domvanalimab
Source: News